Recently, Flora Growth Corp. (NASDAQ:FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced the addition of Vessel founder and CEO, James Choe, to its executive team. “We are excited not only to have added an incredible company like Vessel to our brand portfolio but to be welcoming such a skilled entrepreneur as James Choe to our executive team,” said Luis Merchan, CEO of Flora Growth. “James brings an unparalleled passion to the organization. He has always been a people-first leader, and his ability to craft a company culture and strategy built-in service of the team has already started to create tangible results. We look forward to him growing his contributions.” Founded by Choe in 2018, Vessel is an industry leader in premium cannabis consumption technology and accessories (1)
So what’s the buzz around FLGC?
As per a recent press issued by the company (2):
– Flora’s research division, Flora Pharma, filed USPTO provisional patent application on a cannabinoid-based formula
– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under a EUA from INVIMA (Colombian FDA)
– Breakthrough research intends to explore a preventative application against the SARS-CoV-2 (COVID-19) virus for the patent-pending cannabinoid formulation
– If approved, Flora’s formulation would be the first product containing cannabinoids approved by the Colombian government for use against the SARS-CoV-2 (COVID-19) virus. Could Flora Growth Corp. and its investors may be in for a heck of a bullish ride in 2022? As always, conduct your own due diligence.
Coronavirus vaccine stocks to watch for include Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), Johnson & Johnson’s (NYSE:JNJ), AstraZeneca (NASDAQ:AZN), Novavax (NASDAQ:NVAX), Ocugen (NASDAQ:OCGN) and Vaxart (NASDAQ:VXRT).